23andMe, once a standout in direct-to-consumer genetic testing, has seen its momentum fade and market value fall sharply. Its setback highlights tough commercialization hurdles—costs, competition, and sustained demand—that could influence how India’s genetic-testing market grows. Yet the disruption may also open room for smarter, locally aligned offerings and stronger partnerships across healthcare.
Orchid Pharma, once abandoned by investors, is hitting a major milestone with its first novel antibiotic drug. The company outlicensed the experimental therapy to Germany’s Allecra Therapeutics, which has now secured crucial approvals from the US FDA and a European drug regulator. Developed by Indian scientists in 2008, the breakthrough aims to strengthen the global fight against bacterial infections.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
India is rapidly expanding its bioeconomy, rising from roughly $10 billion in 2014 to more than $195 billion in 2025, according to Jitendra Singh. The government’s direction points to reaching a $300-billion milestone by 2030, highlighting momentum in biotech, research, and bio-based industries as policymakers aim to scale impact.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
